Biodesix to present real-world clinical, economic data for Nodify Lung testing at ATS 2026

Biodesix, Inc.

Biodesix, Inc.

BDSX

0.00
  • Biodesix flagged new real-world clinical and health-economic evidence for its Nodify Lung testing strategy, with results scheduled for presentation at American Thoracic Society annual meeting May 15-20, 2026.
  • Data from academic centers and community hospitals indicate blood-based risk stratification can support earlier lung cancer detection, steer pulmonary nodule management, expand patient access, and improve care pathways.
  • Additional analyses compare biomarker-led approaches with imaging-led workups, aiming to show potential system-level efficiency gains in nodule evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110917PRIMZONEFULLFEED9717147) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.